TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06158854: An Open-Label Phase 1/2 Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) in AL Amyloidosis

Sponsor: AbbVie · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 76 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$2,785,875

Rescue Site Savings

+$1,847,475

Unlock Full NCT06158854 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06158854 Rescue Dossier →